Autopsy and Informatics Analysis Evidence Disturbed Haemostasis Progress in COVID-19: Medical Records from 407 Patients

Tiebin Jiang  
central south university

Bo Lv  
tongji university

Hongxia Liu  
china university of political science and law

Shiwen He  
central south university

Guogang Zhang  
central south university

Chanyi Li  
tongji university

Wanqiong Li  
tongji university

Weilin Li  
hunan yuanpin cell technology

Yaqi He  
central south university

Tong Zhang  
central south university

Yunyun Wang  
Huazhong University of Science and Technology

Wu Mo  
hunan yuanpin cell technology

ning yi  
hunan yuanpin cell technology

Luying Peng  
tongji university

Ying Li  
central south university

Chunhong Ruan  
central south university

Chengyuan Li  
central south university

Yaqi Liu  
central south university

Peipei Luo  
central south university

Huan Jiang  
central south university

zhigang xue (✉ xuezg@tongji.edu.cn )  
Tongji University School of Medicine  https://orcid.org/0000-0001-7715-1403

Liang Liu  
Huazhong University of Science and Technology

Wenjun Wang  
hunan yuanpin cell technology
Abstract

Background: The progress of coagulation in COVID-19 patients with confirmed discharge status (decease or discharge) and the combination of the autopsy with the complete coagulation parameters were not well studied.

Objective: To clarify the thrombotic phenomena with coagulation progress in COVID-19 patients based on epidemiological statistics combining the autopsy and informatics analysis.

Methods: Using 9 autopsy results with COVID-19 pneumonia and the medical records of 407 patients including 39 deceased ones whose discharge status was certain, time-sequential changes of 11 relevant indices within mild, severe and critical infection throughout hospitalization according to the Chinese National Health Commission (NHC) guidelines were evaluated. Informatics tools were applied to calculate the importance of 11 indices and the correlation between those indices and the severities of COVID-19.

Results: At the beginning of the hospitalization, platelet (PLT) had a significant decrease in critically ill patients. Blood glucose (GLU), prothrombin time (PT), activated partial thromboplastin time (APTT), and D-dimer in critical patients were higher than those in mild and severe during the whole admission period. The International Society on Thrombosis and Haemostasis (ISTH) disseminated intravascular coagulation (DIC) score also showed the high DIC level in critical patients. At the relatively late stage of non-survivors, the temporal changes of PLT count, PT, and D-dimer were significantly different from survivors. A random forest model indicated that the most important feature was PT, followed by D-dimer, indicating their positive associations for the severities of disease. Autopsy data from 9 deceased patients also showed the DIC phenomena with prolonged PT, APTT, less PLT count and thrombosis in multiple organs.

Conclusions: Combining autopsy data, time-sequential changes and informatics methods to explore the coagulation relevant indices among the different severities of the disease, helps guide the therapy and detect the prognosis in COVID-19 infection.

Essentials

The role of haemostasis-related indices in different severities of COVID-19 remains to be clarified.

Autopsy, coagulation indices after admission or before outcome, and informatics analysis were used to examine haemostasis process and importance of related parameters.

Persistent abnormalities of coagulation parameters during hospitalization indicated poor prognosis.

Prothrombin time, D-dimer, blood glucose, and age had been demonstrated the most important parameters related to the severities of COVID-19.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China and associated with an outbreak of coronavirus disease 2019 (COVID-19) that affected more than 9 million patients with more than 480 thousand deaths globally as of July 18th, 2020.1-4 The coagulation changes in the SARS-CoV-2 infected patients are now described as the COVID-19 associated coagulopathy (CAC)5-8. A few clinical reports have been published on patients with COVID-19 who undergo complete autopsy.9-17 Notably, several cases find a high incidence of venous thromboses and embolisms as the direct cause of death.18-20 CAC correlated thrombotic phenomena in COVID-19 deaths have been suggested its significant poor prognostic features.12,21-24 However, the progress of coagulation in COVID-19 patients with confirmed discharge status (decease or discharge) and the combination of the autopsy with the complete coagulation parameters were not well studied.

Here we reported the pathological features of COVID-19 patients with thrombotic phenomena from autopsy and the coagulation disease progress among mild, severe, and critical patients from one hospital in Wuhan, China. Moreover, we also investigated the difference between survivors and non-survivors in patients with critical infection. Last but not least, we evaluated the correlation and contribution of those features regarding the severity of patients by informatic tools.

Methods

Patients

We collected autopsy data from 9 deceased patients and clinical data from 407 patients in one hospital in Wuhan. All patients were confirmed COVID-19 pneumonia according to the Chinese National Health Commission (NHC) guidelines (7th trial edition) for COVID-19 pneumonia. Briefly, the patients with SARS-CoV-2 positive using RT-PCR were further confirmed pneumonia using computed tomography (CT) scanning. Patients’ medical records contain the essential information and values of detection indices during the whole process from admission to discharge (or decease).
**Autopsy and histological examination**

We performed full-body autopsies on 9 deceased persons with SARS–CoV-2 positivity as soon as possible after taking proper safety precautions at the bio-safety level 3 (BSL-3) following guidelines from the industrial standards of public safety of the People's Republic of China. Tissue samples for histopathologic examination were fixed in buffered 4% formaldehyde and processed via standard procedure to slides stained with hematoxylin–eosin (H&E stain). All the hematological indices were collected for the last testing before decease.

**Data Collection and Procedures**

We reviewed the electronic clinical charts, examination records, and laboratory findings for 407 COVID-19 patients (including 39 deceased patients). During the whole process from admission to discharge (or death), time-sequential investigations including 11 indices, six of which were haemostasis related indices detected by the kits from Simons (German) using Sysmex 5100 (Japan) – platelet (PLT), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-dimer, and five of which were lab parameters detected by the kits from Leadman (China) using Hitachi Automatic Analyzer 7600 (Japan) — blood glucose (GLU), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) were extracted for subsequent analyses. Other clinical characteristics including age, gender, major comorbidities (coronary artery disease [CAD], hypertension [HTN], and diabetes mellitus [DM]), discharge status (survive or die) and the hospitalization time were also analyzed in our study. Following data extraction, those patients were divided into 3 groups (mild, severe or critical) according to the NHC guidelines for COVID-19 pneumonia. Furthermore, we focused on the temporal changes of these indices between 39 non-survivors and 42 survivors in the critical group to assess the coagulation process of disease deterioration. In addition, correlation using Pearson method and a random forest model was calculated for patient classification for evaluate the importance of 11 indicator for the process of COVID-19. For DIC analysis, the International Society on Thrombosis and Haemostasis (ISTH) diagnostic criteria were applied to all the patients.

**Case Definitions**

Mild infection, severe infection, and critical infection were characterized throughout the entire hospitalization according to NHC's guidelines. Briefly, mild infection is characterized with mild symptoms, fever, respiratory symptoms, and imaging findings of pneumonia. Severe infection is with any of the following appears: shortness of breath (RR>30 times/min), oxygen saturation ≤93%, PaO2/FiO2 ≤300 mmHg. Critical infection is with any of the following appears: respiratory failure requires mechanical ventilation, shock, other organ failure requires ICU monitoring treatment.

**Pearson Correlation Coefficient and Random Forest Model Analysis**

We labeled the male as 1 and female as 0 in random forest model. Due to the limitations of our detection system, the reportable range of D-dimer and TT were 0.22-21 μg/mL and 13-240 s, respectively. Therefore, when it was reported out of this level (e.g. >21 μg/mL for D-dimer), we corrected those values the barrier of the reportable range (e.g. >21 μg/mL for D-dimer as 21 μg/mL). We also labeled the severity of patients as 1 for mild syndrome, 2 for severe syndrome, and 3 for critical syndrome. Then all data were put into one file to calculate the Pearson correlation coefficient (R, 3.6.1, package ‘gpair’) and random forest model (Python 3.7) according to previous reports. Briefly, when constructing the model, the decision tree is enated by CART algorithm using Gini index (also identified as importance index in our study). Gini index represents the impurity level of the model and the Gini index is smaller, the lower purity. In the classification problem, assuming there are K categories, the probability of the kth category is pk, the Gini index formula is as follows:

See formula 1 in the supplementary files section.

We then used Gini index gain as the basis of selecting feature of decision tree, as the following formula:

See formula 2 in the supplementary files section.

We choose the maximum value of Gini index gain as the splitting characteristic, the node is used as the split condition.

**Statistical Analysis**

Descriptive analyses of categorical variables and baseline indices were expressed as median [interquartile range (IQR)], or number (%). Mean and standard error were also used to display the line charts of indices changes. Proportions for categorical variables were compared using the χ² test. Continuous variables were compared using Wilcoxon rank sum test. These statistical analyses were performed using R (version 3.6.1) and the graphs were drawn using GraphPad prism (version 8.0.2).

**Role of funding source**

None of the funders had any role in the study design, data collection, analysis, interpretation or in the writing of the article and the decision to submit it for publication. Independence from funders and sponsors were confirmed by the researchers.
Results

Complete autopsies of 9 deceased COVID-19 patients (5 males and 4 females) with 15 median hospitalization days (IQR, 10-22) before death were performed (Table 1). The median of ages was 67 years old (IQR, 63-78). Except for the missing comorbidity records of 2 cases (cases 6 and 9), the other 7 cases all had comorbidities. To be specific, 7/7 cases had the comorbidity of hypertension, 2/7 (cases 1 and 4) of cerebral infarction, 2/7 (cases 5 and 8) of coronary artery disease, and 1/7 (case 7) of gout. Of note, one case (case 5) had not only hypertension and coronary artery disease but also renal dysfunction, lacunar infarction, and chronic bronchitis with emphysema. 8/9 cases died mainly due to the respiratory failure with multiple organ failure and the other 1/9 died due to sudden cardiac death from acute coronary heart disease.

Besides the diffuse alveolar damage in the lung, the predominant histological findings were hyaline thrombi among all the 9 deceased patients (Figure 1). To be specific, 9/9 cases showed microthrombi in hilar arteriole, alveolar capillary and interstitial vascular lumen of the lung, 4/9 (1, 2, 3, and 5) in the subarachnoid arteriole and parenchymal small endovascular lumen of the brain, 4/9 (1, 2, 3, and 5) in the small vascular lumen of the spleen, 2/9 (cases 2 and 9) within the kidney, and 1/9 (case 4) in coronary artery lumen together with hemorrhage. To evaluate the coagulation state before death, we also extracted the last hematological indices relevant to coagulation, i.e. platelet, prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimer in these cases when they were alive (Table 1). The ISTH DIC scores in 8/9 cases matched the grade of DIC (≥5 points).

The autopsy results of thrombi in the major organs of the body and their DIC before death strongly indicated coagulation abnormalities in COVID-19 patients (Table 1, Figure 1). Together with previous reports showing the high relevance of blood glucose, total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein with coagulation,30-33 we then included those indices in our clinical data analyses. The clinical time-sequential data included 407 hospitalized patients with confirmed COVID-19. Their demographic and clinical characteristics were shown in Table 2. The median (IQR) age was 62.0 years (51.0-58.0) with the overall range from 6 years to 92 years; 51.8% of the patients were from 40 to 65 years of age. A total of 49.9% were female. Of all the patients, 184 (45.2%) had at least 1 of the following 3 comorbidities: coronary artery disease (40 [9.8%]), hypertension (144 [35.4%]), and diabetes (72 [17.7%]). Since all the patients included in this study had either been discharged from hospital with SARS-CoV-2 negativity (368 [90.4%]) or deceased (39 [9.58%]), the median duration of hospitalization was countable at 15 days (8.0-25.0).

Among all the 407 patients with their different symptoms throughout the hospital stay, 253 patients (62.2%) showed mild infection, while 73 patients (17.9%) showed severe infection, and 81 patients (19.9%) showed critical infection. All relevant clinical records were reviewed to classified the patients into critical, severe, or mild groups according to the Chinese National Health Commission (NHC) guidelines (7th trial edition) for COVID-19 pneumonia.26 The patients with critical or severe infection were significantly older than those with mild infection (median [IQR] age, 65.0 [57.0-72.0] or 67.0 [60.0-73.0] years vs 59.2 [45.0-59.0] years; both P values < 0.0001) and more likely to stay longer at hospital after admission (median 19.0 days [7.0-35.0] or 21.0 [14.0-26.0] vs 13.0 [8.0-22.0]; both P values < 0.001), while there was no difference between severe ones and critical ones (P = 0.5996 for age and P = 0.2806 for hospital stay). Moreover, compared to the mild infected patients, patients with severe infection were more likely to have other underlying comorbidities (47 [64.4%] vs 98 [24.1%]; P = 0.0001) especially hypertension (36 [49.3%] vs 77 [30.4%]; P = 0.0028) (Table 2, Table S1).

However, those 81 critical patients showed slightly close features of the underlying comorbidities to the mild ones (39 [48.1%] in critical ones, P = 0.1339) and no significant difference of hypertension proportion between them (31 [38.3%] in critical ones, P = 0.1894) (Table S1). Furthermore, despite no statistically significant difference (P = 0.2806), the median hospitalization days of critical patients were slightly shorter than that of severe ones (19.0 [7.0-35.0] vs. 21.0 [14.0-26.0]). This led us to think about whether the non-survivors displayed any difference in the critical group.

Table S2 demonstrated that when compared with the survivors (42 (51.9%) patients in critical group) in the critical group, fewer non-survivors had underlying comorbidities (13 [33.3%] vs 26 [61.9%]; P = 0.01), such as hypertension (8 [20.5%] vs 23 [54.8%]; P = 0.002) and diabetes mellitus (3 [7.7%] vs 12 [28.6%]; P = 0.02). 39 non-survivors also had shorter hospital stay after admission than that of 42 survivors (median 10.0 days [6.5-16.5] vs 35.0 [21.3-40.5]; P < 0.0001). In addition, those comorbidities percentages of comorbidities and hospital duration in survivors were more similar to the severe group than those in non-survivors from the critical group (Table 2).

To determine the major hematological features that appeared during COVID-19 thrombogenic progression, the temporal changes of 11 clinical laboratory indices, including platelet (PLT), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-dimer, blood glucose (GLU), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL), were tracked on admission until outcome (Table S3). All the 407 patients with definite discharge status were analyzed and displayed using the line chart (Figure 2). During hospitalization, most patients had increased D-dimer, and those with critical infection stay significantly higher D-dimer after admission until the outcome. Intriguingly, PLT in the critical patients showed a marked down on admission, kept the counts low until day 14 (both P < 0.05 compared to mild and severe patients [Table S3]), and then gradually increased. In addition, the indices, e.g. PT, and GLU in critical patients showed persistent prolonged time, higher score or higher level during the hospitalization than those in severe or mild patients, while
others, e.g. TC and HDL in the critical patients were lower at the initial stage and stayed a relatively low level until the outcome. On the other hand, indices e.g. LDL exhibited their changes at the late stage and TT was intermittently prolonged after admission in the critical patients while APTT, FIB, and TG had no discernable difference among patients with different levels of severity during hospitalization. We also found the persistent high DIC score in the critical patients during whole hospitalization using ISTH DIC scoring system.

To evaluate the severity of the coagulation state in patients with different disease levels, we also ought to evaluate the percentages of 11 indices' peak value in every individual that ever reached out of normal range during hospitalization. Table S4 and Table S5 summarized the median (IQR) of the level of all the maximum values of 11 indices in every individual patient during the hospitalization, the proportions of out-of-normal-range values of all the patients with different levels of severity and their statistic test results. In line with the previous findings, the median concentrations of D-dimer (μg/mL) in all types were higher than the normal range (all patients, 1.15 [0.39-3.18]; normal range, 0-0.5). Nonetheless, critical patients showed the significantly higher level of D-dimer than those with the other two types (critical median [IQR] vs severe median [IQR] or mild median [IQR]; 16.77 [3.21-12.9] vs 1.60 [0.78-2.94] or 0.53 [0.28-1.39]; two P both < 0.0001). Other coagulation parameters i.e. PT (16.15 [15.6-21.9] vs 14.3s [13.9-14.8] or 14.0s [13.4-14.5]; two P both < 0.0001), APTT (52.9s [44.1-68.7] vs 43.6s [39.9-47.9] or 40.5s [37.8-44.0]; two P both < 0.0001) and TT (20.0s [17.3-27.0] vs 17.4s [16.8-17.7] or vs 16.8 [16.1-17.8]; two P both < 0.0001) were also prolonged in this peak value evaluation. Consistently, the out-of-normal-range portions of those coagulation parameters in critical patients were significantly larger than those in severe or mild patients, e.g. D-dimer (79/80 [98.8%] vs 64/72 [88.9%], P =0.0101; or vs 127/247 [51.4%], P < 0.0001), similar in the DIC grades.

Our autopsy results and 81 critical patients strongly suggested the difference existing between survivors and non-survivors, so the progression analyses of laboratory hematological indices were also taken to evaluate the severity of coagulation. Since the destinations of all patients were confirmed either discharged with SARS-CoV-2 negativity or deceased, we defined the date of discharge or decease as day 1 before outcome and the previous dates increased backward (Figure 3, Table S6). Interestingly, most indices of survivors and non-survivors shared similar trends, medians, and portions of abnormal values with the whole critical patients. However, when dividing the critical patients into survivors and non-survivors, several indices exhibited a significant difference between them. Combining analysis with the maximum values of individual patients, non-survivors presented with fewer platelets (<10^9/L) [216.0 [142.5-273.5] vs 287.5 [199.0-370.0]; P = 0.0035), prolonged prothrombin time (20.2s [18.1-25.3] vs 16.7s [15.3-18.0]; P < 0.0001), elevated D-dimer (21.00 μg/mL [13.42-21.00] vs 6.79 μg/mL [2.82-20.61]; P = 0.0013) and DIC score (6 [5-7] vs 5 [5-6]; P = 0.0002) than survivors (Table S7, Table S8), strikingly when it came close to the destination date (P = 0.0027 and P = 0.0051 for PLT and PT at day 11 before outcome, respectively; P = 0.0063 and P = 0.0193 for D-dimer at day 12 before outcome)(Figure 3, Table S6). Notably, while no obvious change could be found when divided all patients into 3 groups (Figure 2), the subgroup of non-survivors manifested a significantly higher level of fibrinogen than that of survivors at days 7 and 9 before outcome (Figure 3, Table S6).

To further explore the underlying correlation between these groups, the heat map was applied to visualize the Pearson correlation coefficient between each clinical feature or laboratory indices (Figure 4). "Severity" in the heatmap indicated the severities of COVID-19, i.e. mild, severe, and critical classifications. As indicated by the heat map, the features that positively correlated with patient classifications included coagulation indices e.g. PT (Pearson correlation 0.46), APTT (Pearson correlation 0.31), and D-dimer (Pearson correlation 0.46) and others e.g. GLU (Pearson correlation 0.42) whereas indices including TC (Pearson correlation -0.42), HDL (Pearson correlation -0.54), and LDL (Pearson correlation -0.54) showed a significantly negative correlation with patient classifications. We further applied those data to the normal distribution curve to estimate those features’ relationship with the severity (Figure 4). Unlike age-severity distribution with the critical group’s mean between severe group and mild group (Figure 4), coagulation indices-severity distributions including PT, APTT, and D-dimer all complied with the mild-severe-critical distribution positively and other indices such as TC, HDL, and LDL negatively (Figure S1). To explore which indices played an indispensable role, a random forest model was constructed according to patient classifications. The best accuracy of the model is 83.8%, the maximum depth of the tree is 9, and the number of classifiers is 50 (Figure S1). Then the model showed us the importance of each feature (Figure 4, Figure S1). The most important feature was PT, followed by D-dimer. These two features contributed to the 40% importance of total. The red dotted line together with the black one separated the features that totaled 90% importance. Taken together, those data suggested the important role of coagulation and hematological indices during the deterioration of COVID-19 progress.

**Discussion**

This study combined 9 autopsy results with the epidemiological and clinical characteristics of 407 COVID-19 patients to explore the dynamic changes in coagulation function profiles during the entire hospitalization. Based on the evaluation of 11 hematological indices on admission to discharge, we found several interesting phenomena that were not reported before. These hematological indices such as PT, APTT, PLT, and D-dimer showed significant changes among different types of patients. Notably, in our study, deceased patients were categorized in critical patients. Mortality among critically ill patients was as high as 48.1%. Moreover, a high level of FIB in the non-survivors at days 5-10 before the outcome was found in our study, which was different from previous reports. Considering the same critical patients as the control group and the intact period of hospitalization, our data were more likely to elucidate the underlying coagulation process. In the same period when FIB was higher in the non-survivors, the other haemostasis-related indices such as PLT, PT, and D-dimer were all deviated from the normal range, indicating hypercoagulation state in the non-survivors. Of note, PLT was significantly lower in the critical group, and then gradually went up at the late stage.
of hospitalization (Figure 2). However, when separating the critical group into subgroups, we found that there were not so many critical changes in the survivors and we could reason that the decline of PLT was the result of non-survivors’ thrombocytopenia (Figure 2, Figure 3). In concert with the previous study\textsuperscript{5}, levels of D-dimer showed two marked peaks during hospitalization in non-survivors (Figure 3), suggesting the coagulation activation during thrombosis. Considering so many coagulation related abnormalities, we also calculated the ISTH DIC score to evaluate the DIC state in all patients along the time axis. Despite the increased level of FIB in non-survivors, the DIC score showed the critical patient reaching the limit nearly all the time with no significant difference in its survivor or non-survivor subgroup (Figure 3). This phenomenon of DIC together with the observation of thrombotic from autopsy histological results showed different disturbed haemostasis state among different levels of severity in COVID-19 patients.

Other haemostasis relevant indices are LDH and HDL. Surprisingly, our observation along the hospitalization showed a significant decrease in these 2 indices in critical patients instead of an increase in the previous report.\textsuperscript{35} Since the protective effect of HDL through inhibiting blood vessel aggregation, inflammation, oxidation, endothelial damage and thrombosis in several hematological diseases\textsuperscript{36}, the low-level HDL and LDL in our observation in critical patients indicated the disturb hematological system, which might contribute to the disease deterioration. Although GLU exhibited much higher in critical group and diabetes mellitus has been found the risk factor of COVID-19 progression especially for deaths in previous and our studies\textsuperscript{37}, we should still be careful giving suggestions between diabetes and COVID-19 unless more definite conclusions are made through detail researches. Previous studies have shown that several COVID-19 patients have increased concentrations of proinflammatory cytokines such as tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) and interleukin (IL)\textsuperscript{38}, especially induces a cytokine storm that might lead to the activation of the coagulation cascade in severe cases.\textsuperscript{39} Besides, diabetes can also affect vascular abnormalities and promote the increased synthesis of glycosylation end products (AGEs) and pro-inflammatory cytokines, oxidative stress to mediate inflammation.\textsuperscript{40} Taken together, all these showed us the complex CAC progresses in COVID-19 patients with thrombotic complications.

Limitations

Our study has notable limitations. First, the number of patients included in our study is still not large sample, especially for deceased patients. This may bias the proportion of comorbidities and other observations. It would be better to include more patients over the world and among different countries. Second, indices are still not enough to evaluate the comprehensive aspects of thrombogenesis since thrombogenesis is a complex complication especially when a patient is infected with a virus of high infectivity. Third, we start the records from the admission instead of the onset of illness, which might lose part of the coagulation information.

Conclusions

In summary, our study provides the full spectrum of coagulation progress with the definite discharge status and also shows the existence and dynamic changes of DIC along with this progress. Importantly, we combined the autopsy histology and informatics analysis to reveal the significance of haemostasis relevant indices during thrombosis. Those results might help guide the therapy and detect the prognosis in different levels of COVID-19 infections.

Declarations

Contributors

Z.G. Xue, L. Liu, and W.J. Wang designed the study, had full access to all data, and take responsibility for the integrity and accuracy of the data and data analysis. B. Lv, C.Y. Li, W.Q. Li, Y.Q. He, S.W. He and T. Zhang contributed to data analysis. B. Lv, C.Y. Li, and T.B. Jiang contributed to interpreting the analysis. Y.Y. Wang and L. Liu contributed to the autopsy and histological examination. B. Lv and C.Y. Li contributed to the writing of the article. H.X. Liu and G.G. Zhang contributed to the critical revision of the data. All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version.

Data sharing

After the publication of the study findings, the data that support the findings of this study will be available for others from the corresponding author based on reasonable request. We will provide an email address for communication once the data are approved to be shared with others under the supervision of the corresponding author and the NHC’s guidelines.

Declaration of interests

These authors declare no competing interests.

Acknowledgement and Funding
This work was supported by grants from the National Key R&D Program of China (2017YFC1001301 and 2016YFC1000208), National Science Foundation of China (81771651 and 81871820), Key Research and Development Plan of Hunan Province (2020SK3015).

References

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 2020; 323(13): 1239-42.

2. Zhu N, Zhang D, Wang W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019 [published January 24, 2020]. N Engl J Med.

3. World Health Organization. Coronavirus disease (COVID-19) situation reports [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/].

4. Guan Wj, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine 2020; 382(18): 1708-20.

5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 2020.

6. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. Journal of the American College of Cardiology 2020.

7. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis 2020; 18(5): 1094-9.

8. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020.

9. Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann Intern Med 2020.

10. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine 2020; 8(4): 420-2.

11. Barton LM, Duval EJ, Strober E, Ghosh S, Mukhopadhyay S. Covid-19 autopsies, oklahoma, usa. American Journal of Clinical Pathology 2020; 153(6): 725-33.

12. Yao X, Li T, He Z, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua bing li xue za zhi= Chinese journal of pathology 2020; 49: E009-E.

13. Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology: Cardiothoracic Imaging 2020; 2(2): e200067.

14. Zhang H, Zhou P, Wei Y, et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Annals of internal medicine 2020; 172(9): 629-32.

15. Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Modern Pathology 2020: 1-8.

16. Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Annals of Internal Medicine 2020.

17. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Medicine 2020: 1.

18. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology 2020.

19. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 2020.

20. Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. Journal of Thrombosis and Haemostasis 2020; 18(6): 1469-72.

21. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis 2020; 18(5): 1023-6.

22. Wichmann D, Sperhake J-P, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Annals of Internal Medicine 2020.

23. Dolnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. Journal of Thrombosis and Haemostasis 2020.

24. Mackman N, Antoniak S, Wolberg AS, Kasthuri R, Key NS. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arteriosclerosis, thrombosis, and vascular biology 2020; 40(9): 2033-44.
25. Hardy M, Lecompte T, Douxls J, et al. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thrombosis journal 2020; 18(1): 1-16.

26. Wei X, Zeng W, Su J, et al. Hypolipidemia is associated with the severity of COVID-19. Journal of Clinical Lipidology 2020.

27. Taylor Jr FB, Toh C-H, Hoots KW, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and haemostasis 2001; 86(11): 1327-30.

28. Islam MK, Alam MM, Rony MRAH, Mohiuddin K. Statistical Analysis and Identification of Important Factors of Liver Disease using Machine Learning and Deep Learning Architecture. Proceedings of the 2019 3rd International Conference on Innovation in Artificial Intelligence; 2019; 2019. p. 131-7.

29. Wang H, Liu Y, Huang W. Random forest and Bayesian prediction for Hepatitis B virus reactivation. 2017 13th International Conference on Natural Computation, Fuzzy Systems and Knowledge Discovery (ICNC-FSKD); 2017: IEEE; 2017. p. 2060-4.

30. van der Toorn FA, de Mutsert R, Lijfering WM, Rosendaal FR, van Hylckama Vlieg A. Glucose metabolism affects coagulation factors: The NEO study. Journal of Thrombosis and Haemostasis 2019; 17(11): 1886-97.

31. Schulman S, Bendapudi P, Sharda A, et al. Extracellular thiol isomerases and their role in thrombus formation. Antioxidants & redox signaling 2016; 24(1): 1-15.

32. Chung DW, Chen J, Ling M, et al. High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood, The Journal of the American Society of Hematology 2016; 127(5): 637-45.

33. Holy EW, Akhmedov A, Speer T, et al. Carbamylated low-density lipoproteins induce a prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo. Journal of the American College of Cardiology 2016; 68(15): 1664-76.

34. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj 2020; 368.

35. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet 2020.

36. Li H, Li DQ, Li XX, Wang LQ. The association between oxidized low-density lipoprotein antibodies and hematological diseases. Lipids in health and disease 2016; 15(1): 190.

37. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Research and Clinical Practice 2020; 108142.

38. Mehta R, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 2020; 395(10229): 1033-4.

39. Hozumi H, Russell J, Vital S, Granger DN. IL-6 Mediates the Intestinal Microvascular Thrombosis Associated with Experimental Colitis. Inflammatory bowel diseases 2016; 22(3): 560-8.

40. Knapp S. Diabetes and infection: Is there a link?-A mini-review. Gerontology 2013; 59(2): 99-104.

Tables

Table 1. Demographic and clinical characteristics and laboratory indices of 9 autopsy cases
Table 2. Demographic and clinical characteristics of 407 patients with COVID-19

| Characteristics                              | All Patients (n=407) | Mild (n=253) | Severe (n=73) | Critical (n=81) |
|----------------------------------------------|---------------------|--------------|---------------|-----------------|
| Age - Median (IQR) - years                   | 62.0 (51.0-69.0)    | 59.0 (55.0-66.0) | 67.0 (60.0-73.0) | 65.0 (57.0-72.0) |
| Distribution - No. (%)                       | 64                  | 61           | 67            | 73              |
| Gender - No. (%)                              | 293 (49.9)          | 178 (50.1)   | 111 (43.9)    | 117 (43.9)      |
| Female                                       | 203 (49.9)          | 124 (57.6)   | 78 (39.7)     | 75 (39.5)       |
| Male                                         | 294 (50.1)          | 129 (42.4)   | 33 (30.3)     | 36 (30.5)       |
| Major Comorbidities - No. (%)                | 184 (45.2)          | 104 (41.1)   | 76 (39.1)     | 78 (39.1)       |
| Coronary artery disease                      | 40 (9.8)            | 17 (6.6)     | 11 (15.1)     | 12 (14.8)       |
| Hypertension                                 | 11 (2.7)            | 7 (2.8)      | 4 (5.5)       | 3 (3.7)         |
| Diabetes mellitus                            | 72 (17.7)           | 43 (16.9)    | 18 (24.6)     | 34 (42.3)       |
| Clinical outcome - No. (%)                   | 368 (90.4)          | 253 (100)    | 73 (100)      | 42 (51.9)       |
| Discharged                                   | 39 (9.6)            | 0            | 0             | 39 (48.1)       |
| Hospital stay - Median (IQR) - days          | 13.0 (10.0-23.0)    | 13.0 (7.0-22.0) | 21.0 (14.0-26.0) | 19.0 (7.0-35.0) |

Percentages may not total 100 because of rounding.

Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range.